AIMS: Cytochrome P450 2A6 (CYP2A6) is a human enzyme best known for metabolizing nicotine and nitrosamine precarcinogens. Our aim was to discover and characterize new CYP2A6 alleles in a population of Black African descent. MATERIALS & METHODS: We used cloning, sequencing and genotyping of genomic DNA to discover new variants, and in vivo nicotine pharmacokinetic phenotyping to characterize the functional effect of the new alleles. RESULTS: Four new CYP2A6 alleles, CYP2A6*4G, *4H, *1B4 and *1L, were discovered and characterized in a population of Black African descent. The two new deletion alleles, CYP2A6*4G and *4H, are distinguished by different crossover junctions at 7.9 and 7.8 kb downstream of the CYP2A6 +1ATG start site, respectively; their combined allele frequency is 1.6%. The new gene conversion alleles, CYP2A6*1B4 and CYP2A6*1L, contain 27 and 10 bp of CYP2A7 sequence in the CYP2A6 3 -flanking region, respectively; their combined allele frequency is 7.3%. CYP2A6*4 appears to associate with lower CYP2A6 activity in vivo, while CYP2A6*1L does not; however, CYP2A6*1L confounds genotyping assays that use the 2A6R3 and 2A6R4 primers. CONCLUSION: As new variants are discovered, the relationships between CYP2A6 genotype, nicotine metabolism, smoking behaviors and tobacco-related cancer risk will be further clarified.
AIMS: Cytochrome P450 2A6 (CYP2A6) is a human enzyme best known for metabolizing nicotine and nitrosamine precarcinogens. Our aim was to discover and characterize new CYP2A6 alleles in a population of Black African descent. MATERIALS & METHODS: We used cloning, sequencing and genotyping of genomic DNA to discover new variants, and in vivo nicotine pharmacokinetic phenotyping to characterize the functional effect of the new alleles. RESULTS: Four new CYP2A6 alleles, CYP2A6*4G, *4H, *1B4 and *1L, were discovered and characterized in a population of Black African descent. The two new deletion alleles, CYP2A6*4G and *4H, are distinguished by different crossover junctions at 7.9 and 7.8 kb downstream of the CYP2A6 +1ATG start site, respectively; their combined allele frequency is 1.6%. The new gene conversion alleles, CYP2A6*1B4 and CYP2A6*1L, contain 27 and 10 bp of CYP2A7 sequence in the CYP2A6 3 -flanking region, respectively; their combined allele frequency is 7.3%. CYP2A6*4 appears to associate with lower CYP2A6 activity in vivo, while CYP2A6*1L does not; however, CYP2A6*1L confounds genotyping assays that use the 2A6R3 and 2A6R4 primers. CONCLUSION: As new variants are discovered, the relationships between CYP2A6 genotype, nicotine metabolism, smoking behaviors and tobacco-related cancer risk will be further clarified.
Authors: Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale Journal: Clin Pharmacol Ther Date: 2006-11 Impact factor: 6.875
Authors: Donald F Conrad; T Daniel Andrews; Nigel P Carter; Matthew E Hurles; Jonathan K Pritchard Journal: Nat Genet Date: 2005-12-04 Impact factor: 38.330
Authors: Nael Al Koudsi; Jill C Mwenifumbo; Edward M Sellers; Neal L Benowitz; Gary E Swan; Rachel F Tyndale Journal: Eur J Clin Pharmacol Date: 2006-04-28 Impact factor: 2.953
Authors: Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale Journal: J Natl Cancer Inst Date: 2011-07-11 Impact factor: 13.506
Authors: Ajna Hamidovic; Robert J Goodloe; Andrew W Bergen; Neal L Benowitz; Mindi A Styn; Jay L Kasberger; Helene Choquet; Taylor R Young; Yan Meng; Cameron Palmer; Mark Pletcher; Stefan Kertesz; Brian Hitsman; Bonnie Spring; Eric Jorgenson Journal: Neuropsychopharmacology Date: 2011-11-16 Impact factor: 7.853
Authors: Gideon St Helen; Maria Novalen; Daniel F Heitjan; Delia Dempsey; Peyton Jacob; Adel Aziziyeh; Victoria C Wing; Tony P George; Rachel F Tyndale; Neal L Benowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-05-02 Impact factor: 4.254
Authors: Z Desta; Y Kreutz; A T Nguyen; L Li; T Skaar; L K Kamdem; N L Henry; D F Hayes; A M Storniolo; V Stearns; E Hoffmann; R F Tyndale; D A Flockhart Journal: Clin Pharmacol Ther Date: 2011-10-05 Impact factor: 6.875
Authors: M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale Journal: Clin Pharmacol Ther Date: 2009-03-11 Impact factor: 6.875
Authors: Matthew J Binnington; Andy Z X Zhu; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2012-06 Impact factor: 2.089